NCT06616038

Heart Failure Biomarkers

Biomarker Assessment in Heart Failure with Reduced Systolic Function (HFrEF) and Preserved Systolic Function (HFpEF)

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 114 (estimated)
• Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Systemic inflammation is closely associated with the development and progression of heart failure (HF). The study assessed the fibrin/albumin (FAR) ratio, a very important biomarker, as a prognostic indicator of HE. Study population is composed by patients who were addicted with heart failure diagnosed for the first time or already under treatment (NYHA class II-IV) and reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

Detailed description

Prospective, observational, single-center study, which involves the enrollment of patients affected by heart failure of first diagnosis or already in therapy, who will be subjected to an analysis of the Albumin/fibrinogen ratio. Subjects will not be subjected to specific visits or services for the study: clinical and anamnestic data will be collected during routine visits.

Conditions

• Atrial Fibrillation (AF)
• Hart Failure

Interventions

Type	Name	Description
OTHER	Data collection	Given the observational nature of the study, the intervention is a simple data collection

Timeline

• Start date: 2024-10-30
• Primary completion: 2025-08-30
• Completion: 2025-10-30
• First posted: 2024-09-27
• Last updated: 2024-09-27

Locations

2 sites across 1 country: Italy